Metformin

Generic Name: Metformin

Brand Names: Actoplus Met, Avandamet, Fortamet, Glucophage, Glucovance, Glumetza, Glycon, Invokamet, Janumet, Jentadueto, Kazano, Kombiglyze, Komboglyze, Qternmet, Riomet, Segluromet, Synjardy, Trijardy, Velmetia, Xigduo

Drug Type: Small Molecule

Chemical Formula: C_₄H_₁₁N_₅

CAS Number: 657-24-9

Unique Ingredient Identifier: 9100L32L2N

Background: Metformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of type II diabetes.
...

Indication: Metformin immediate-release formulations

Metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients ≥10 years old with type 2 diabetes mellitus.

Metformin extended-release tablet (XR)
...

Associated Conditions: Cardiovascular Mortality, End Stage Renal Disease (ESRD), Hospitalizations, Polycystic Ovarian Syndrome (PCOS), Type 2 Diabetes Mellitus, Decreased estimated glomerular filtration rate

Associated Therapies: -

Clinical Trials

A Study Assessing Saxagliptin Treatment in Type 2 Diabetic Subjects Who Are Not Controlled With TZD Therapy Alone

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Saxagliptin
Drug: Placebo
Drug: pioglitazone
Drug: rosiglitazone
Drug: metformin

First Posted Date: 2006-02-24

Last Posted Date: 2015-04-07

Lead Sponsor: AstraZeneca

Target Recruit Count: 565

Registration Number: NCT00295633

Locations: 🇺🇸
Sunbelt Research Group, Llc, Mobile, Alabama, United States
🇺🇸
Loma Linda Va Healthcare Systems, Loma Linda, California, United States
🇺🇸
Mouhaffel, Assad H., West Monroe, Louisiana, United States

and more 77 locations

Evaluation of Glucose Lowering Effect, Safety and Tolerability of CS-917

Phase 2

Completed

Conditions: Diabetes Mellitus, Type 2

First Posted Date: 2006-02-13

Last Posted Date: 2007-09-11

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 400

Registration Number: NCT00290940

Efficacy and Safety of Alogliptin Combined With Metformin in Participants With Type 2 Diabetes Mellitus

Phase 3

Completed

Conditions: Diabetes Mellitus

Interventions: Drug: Alogliptin and metformin
Drug: Metformin

First Posted Date: 2006-02-03

Last Posted Date: 2012-02-03

Lead Sponsor: Takeda

Target Recruit Count: 527

Registration Number: NCT00286442

Impact of Metformin in Teens With Polycystic Ovary Syndrome (PCOS) on Oral Contraceptive Therapy

Phase 3

Completed

Conditions: Polycystic Ovary Syndrome

Interventions: Drug: Metformin
Drug: Oral Contraceptive Pill
Behavioral: Quality of Life Questionnaire
Behavioral: Lifestyle Management Program
Procedure: Oral Glucose Tolerance Test
Procedure: Blood work
Procedure: Abdominal Ultra Sound
Procedure: Dual-energy x-ray absorptiometry (DEXA scan)
Drug: placebo

First Posted Date: 2006-01-30

Last Posted Date: 2015-05-15

Lead Sponsor: University of Rochester

Target Recruit Count: 36

Registration Number: NCT00283816

Locations: 🇺🇸
University of Rochester Medical Center, Rochester, New York, United States

Beta Cell Function Tests Over Time In Patients With T2dm Randomized To Metformin Or Rosiglitazone

Not Applicable

Terminated

Conditions: Type 2 Diabetes Mellitus

First Posted Date: 2006-01-27

Last Posted Date: 2008-10-13

Lead Sponsor: Pfizer

Target Recruit Count: 29

Registration Number: NCT00282945

Locations: 🇮🇱
Pfizer Investigational Site, Jerusalem, Israel

Life Style Modifications Prevents Type 2 Diabetes in Asian Indians

Phase 1

Completed

Conditions: Diabetes

First Posted Date: 2006-01-19

Last Posted Date: 2006-01-24

Lead Sponsor: M.V. Hospital for Diabetes

Registration Number: NCT00279240

Locations: 🇮🇳
Diabetes Research Centre & MV Hospital for Diabetes, Chennai, Tamilnadu, India

Diabetes Study With Rosiglitazone Monotherapy Versus Metformin Or Glyburide/Glibenclamide

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2

First Posted Date: 2006-01-19

Last Posted Date: 2017-11-29

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 4426

Registration Number: NCT00279045

Locations: 🇬🇧
GSK Investigational Site, Wigan, United Kingdom

ELEONOR STUDY: Insulin Glulisine in Type 2 Diabetes Mellitus.

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Insulin glulisine
Drug: Insulin glargine
Drug: Metformin

First Posted Date: 2006-01-04

Last Posted Date: 2009-12-07

Lead Sponsor: Sanofi

Target Recruit Count: 352

Registration Number: NCT00272064

Locations: 🇮🇹
Sanofi-Aventis Administrative Office, Milan, Italy

Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy

Phase 2

Active, not recruiting

Conditions: Prostate Cancer

Interventions: Drug: Transdermal Oestradiol
Drug: Prednisolone
Drug: Celecoxib
Drug: Docetaxel
Drug: ADT
Radiation: Radiotherapy to the prostate
Drug: Zoledronic Acid
Drug: Metformin
Drug: Abiraterone
Drug: Enzalutamide

First Posted Date: 2005-12-22

Last Posted Date: 2023-04-18

Lead Sponsor: Medical Research Council

Target Recruit Count: 11992

Registration Number: NCT00268476

Locations: 🇬🇧
West Suffolk Hospital, Bury St. Edmunds, England, United Kingdom
🇬🇧
Derbyshire Royal Infirmary, Derby, England, United Kingdom
🇬🇧
Russells Hall Hospital, Dudley, England, United Kingdom

and more 115 locations

A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus Treated With a Stable Dose of Metformin

Phase 2

Completed

Conditions: Diabetes Mellitus Type 2

Interventions: Drug: GK Activator (2)
Drug: Metformin

First Posted Date: 2005-12-16

Last Posted Date: 2016-11-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 220

Registration Number: NCT00266253

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy